3 days popular7 days popular1 month popular3 months popular

Disruption of brain-blood barrier might influence progression of Alzheimer’s

More and more data from preclinical and clinical studies strengthen the hypothesis that immune system-mediated actions contribute to and drive pathogenesis in Alzheimer’s disease. The team of Roosmarijn Vandenbroucke in the Claude Libert Group (VIB/UGent) combined their knowledge and expertise related to inflammation with the expertise in Alzheimer’s disease present in the Bart De Strooper [...]

West African Ebola virus strain less virulent than prototype 1976 strain

Comparison shows delayed disease progression The Makona strain of Ebola virus (EBOV) circulating in West Africa for the past year takes roughly two days longer to cause terminal disease in an animal model compared to the original 1976 Mayinga strain isolated in Central Africa, according to a new National Institutes of Health (NIH) report. The [...]

New drug stalls blood cancer for longer than current common treatment

New data from the Phase III GADOLIN study demonstrated that Gazyvaro, in combination with bendamustine chemotherapy, followed by Gazyvaro alone, reduced the risk of disease worsening or death by 45% in patients with a difficult-to-treat type of blood cancer, compared with bendamustine alone (progression-free survival or PFS; HR=0.55, 95% CI 0.40-0.74, p=0.0001). This means that [...]

Real-life study for YONDELIS® in sarcoma show comparable or better efficacy than clinical trials

Outcomes from 885 patients with soft-tissue sarcoma at 25 French centers were analyzed The study using 885 patients from the RetrospectYon database suggests that treatment with YONDELIS® (trabectedin) can be optimized when given earlier, as second-line therapy, in patients who are likely to obtain clinical benefit The study reinforces the efficacy of this drug in [...]

Reasons for ibrutinib therapy discontinuation in patients with chronic lymphocytic leukemia

About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical trials, according to a study published online by JAMA Oncology. CLL is the most prevalent leukemia in adults and it is not considered curable without an allogeneic (donor) [...]